Regulus Therapeutics (RGLS) – Short Sales
-
Regulus (RGLS) Data Presents Minimal Risk to Gilead (GILD), Baird Says; 'RG-101 Data Looks About as Competitive as Dead Interferons'
-
Regulus Therapeutics (RGLS) Surges Over 150% on Following Positive Interim Results for RG-101 in HCV
-
Back to RGLS Stock Lookup